Industria y Comercio

SUPERINTENDENCIA

Delegatura de propiedad Industrial

División de Nuevas Creaciones

PCT

SOLICITUD

PATENTE DE INVENCIÓN

21. **EXPEDIENTE No.** 06.29537

54. **TÍTULO** COMPUESTO ARTEMISININA

51. **CLASIFICACIÓN INTERNACIONAL** A61K31/336, 31/4706, 31/496, A61P 33/0

71. **SOLICITANTE** GOUQIAO LI JIANPING SONG

DOMICILIO GUANGDONG, CHINA

74. **APODERADO** LAURA MICHELSEN NIÑO

22. **BOGOTÁ, D. C.,** 24-03-06

(FORMA P-10)

1

PETITORIO

Industria y Comercio
SUPERINTENDENCIA

SUPERINDUSTRIA Y COMERCIO
Radicación : 05025537 00000000 Folios: 23
Fecha (AMD): 2006-03-24 16:44:57
Trámite : 411 PCT-PATENT 336 FASE NACI 411 PRESENTAC
Dependencia: 2020 DIVISION DE NUEVAS CREACIONES

FORMULARIO ÚNICO DE SOLICITUD DE PATENTE
PCT
ENTRADA EN FASE NACIONAL : 26-04-2006

① SOLICITUD DE :

[X] Patente de Invención. [ ] Patente de Modelo de Utilidad.

[X] Capitulo I. [ ] Capitulo II.

② SOLICITANTE (71)	Nombre: GUOQIAO LI y JIANPING SONG Dirección: Room 601, Building 68, 12 Airport RD, Guangzhou, Guangdong 510405, China Nacionalidad o Domicilio: CHINA Lugar de Constitución: Teléfono: Fax: E-mail:	IDENTIFICACIÓN C.C. [ ] NIT [ ] C.E. [ ] Otro [ ] Cual ____ Número ____
③ REPRESENTANTE O APODERADO	Nombre: LAURA MICHELSEN NIÑO Dirección: CALLE 93B No. 12 - 48, Of. 204 Teléfono: 601 9660 Fax: 611 4209 E-mail: tum@tumnet.com	IDENTIFICACIÓN C.C. [X] NIT [ ] C.E. [ ] Otro [ ] Cual ____ Número 39.783.287 TP 57.897
④ INVENTOR (ES) (72)	Nombre: GUOQIAO LI y JIANPING SONG Dirección: Room 601, Building 68, 12 Airport RD, Guangzhou, Guangdong 510405, China Nacionalidad o Domicilio CHINA	

⑤ PCT (86)

Solicitud Internacional No. PCT/CN2004/001064 Fecha 20-09-2004

Publicación Internacional No. WO/2005/030197 Fecha 07-04-2005

⑥ Título (54) COMPUESTO ARTEMISININA

⑦ Clasificación Internacional (51) A61K 31/366, A61K 31/4706, A61K 31/495, A61P 33/06

⑧ Prioridad	(33) País de Origen	(32) Fecha	(31) Número de Solicitud
SI [X] NO [ ]	CHINA	26/09/2003	03146951.5

⑨ Comprobante de pago No. 25-23,442 / 25-23,414 Fecha 22-03-06 / 23-03-06

Instrucciones para el diligenciamiento del presente formulario, ver reverso de esta página.

(10) **ANEXOS**

- [X] Comprobante de pago de la tasa de presentación de la solicitud.
- [ ] Documento que acredite la existencia y representación legal cuando el solicitante sea persona jurídica.
- [ ] Poder/es, si fuere el caso.
- [ ] Documento de cesión del inventor al solicitante o a ser cesionario.
- [ ] Declaraciones.
- [X] Copia de la solicitud internacional. (Resumen, descripción, reivindicaciones, dibujos)
- [ ] Traducción de la solicitud internacional al castellano. (Resumen, descripción, reivindicaciones dibujos)
- [ ] Copia del examen preliminar internacional efectuado por la Autoridad Internacional de Examen Preliminar (IPEA).
- [ ] Traducción del examen preliminar internacional efectuado por la IPEA.
- [ ] De ser el caso, copia del contrato de acceso.
- [ ] De ser el caso, documento que acredite la licencia o autorización de uso de conocimientos tradicionales de las comunidades indígenas.
- [ ] De ser el caso, certificado de depósito del material biológico.
- [ ] Acta final 12x12.
- [ ] De ser el caso, información sobre otras solicitudes de patente o títulos obtenidos en el extranjero por el mismo titular o su causante, relacionadas parcial o totalmente con la invención de esta solicitud.
- [X] De ser el caso, modificaciones efectuadas a la solicitud internacional.
- [X] Otros

(11) **FIGURA CARACTERÍSTICA:**

(12) Solicito la concesión de la patente.

NOMBRE: LAURA MICHELSEN RO

FIRMA:

C.I. 38.763.287-0 T.P. 67.897

Instrucciones para la presentación de los anexos, ver reverso de esta página.

3

SUPERINDUSTRIA Y COMERCIO
Radicacion : 06029537
Fecha (RSA): 2006-03-24 16:41:57 Folios: 23
Tramite : 011 PCT-PATENT 378 FASE NACI 411 PRESENTAR
Dependencia: 2020 DIVISION DE NUEVAS CREACIONES

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800176089-2

RECIBO OFICIAL DE CAJA : 06 - 23,147
FECHA : MARZO 22 DE 2006

***** C O N S I G N A C I O N *****

DEPOSITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PAGO	Vr. PAGO
TRIANA URIBE & MICHELSEN	CONSIGNACION	BANCO POPULAR	050-00110-5	48489630	22/03/2006	1,755,000.00

***** C O N C E P T O *****

CANT. NEMOTECNICO		CONCEPTO	TOTAL CONCEPTO
1 50030-01-01	SOLICITUDES	1 TRAMITES DE SOL. DE PATENTE DE IN	463,000.00
		TOTAL : $	463,000.00

SON: CUATROCIENTOS SESENTA Y TRES MIL PESOS

RESPONSABLE : ______________________

RECIBO DE CAJA APLICADO AL EXPEDIENTE No. ______________

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO Folios 23
Radicacion : 06029537 [illegible]
Fecha (AMD): 2006-03-24 15:41:57
Tramite : 011 PCT-PATENTE 390 FASE NACI 411 SOLICITUD
Dependencia: 2020 DIVISION DE NUEVAS CREACIONES

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800176089-2

RECIBO OFICIAL DE CAJA : 06 - 23.429
FECHA : MARZO 23 DE 2006

******* C O N S I G N A C I O N *******

DEPOSITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PGO	Vr. PAGO
TRIANA URIBE & MICHELSEN	CONSIGNACION	BANCO POPULAR	050-00110-6	51161372	23/03/2006	129,660.00

******* C O N C E P T O *******

CANT.	ESTADISTICO	CONCEPTO	TOTAL CONCEPTO
1	50005-01-61 SOLICITUDES	82 INVOCACION DE UNA PRIORIDAD EN NR	130,000.00
		TOTAL : $	130,000.00

SON: CIENTO TREINTA MIL PESOS

RESPONSABLE : ______________________________

RECIBO DE CAJA APLICADO AL EXPEDIENTE No.______________________________

公开文本，由网上检索得到

(12) 按照专利合作条约所公布的国际申请

(19) 世界知识产权组织
国际局

(43) 国际公布日：
2005年4月7日 (07.04.2005)

PCT

(10) 国际公布号：
WO 2005/030197 A1

(51) 国际分类号[7]：A61K 31/536, 31/496, 31/4706, A61P 33/06

(21) 国际申请号： PCT/CN2004/001064

(22) 国际申请日： 2004年9月28日 (28.09.2004)

(25) 申请语言： 中文

(26) 公布语言： 中文

(30) 优先权：
03146961.5 2003年9月26日 (26.09.2003) CN

(71)(72) 发明人/申请人：李国桥(LI, Guoqiao) [CN/CN]；中国广东省广州市机场路12号46栋601室, Guangdong 510405 (CN)。

(72) 发明人；及
(75) 发明人/申请人(仅对美国)：宋健平(SONG, Jianping) [CN/CN]；中国广东省广州市机场路12号46栋601室, Guangdong 510405 (CN)。

(74) 代理人：广州市南锋专利事务所有限公司 (GUANGZHOU NANFENG PATENT AGENT LIMITED)；中国广东省广州市先烈中路100号咨询楼本中心实验楼二楼, Guangdong 510070 (CN)。

(81) 指定国(除另有指明，要求每一种可提供的国家保护)：AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

(84) 指定国(除另有指明，要求每一种可提供的地区保护)：ARIPO(BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)，欧亚专利(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)，欧洲专利(AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)，OAPI(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

本国际公布：
— 包括国际检索报告。

所引用双字母代码和其它缩写符号，请参考刊登在每期PCT公报期刊起始的"代码及缩写符号简要说明"。

(54) Title: COMPOUND ARTEMISININ

(54) 发明名称：复方青蒿素

(57) Abstract: The present invention relates to compound artemisinin tablet which can treat multiple drug-resistant pernicious malaria, tertian malaria and quartan malaria and the relationship children formulation such as granules, suppository, syrup and powder. The compound consists of artemisinin, piperaquine and primaquine. Clinical tests in southeast Asia countries where malaria prevails demonstrate that the compound is high effective and quick effective. It can shorten the period of treatment and the side effects are lowered. The material costs are lowered. The administration is convenience. It can kill off the gametocyte quickly and cut off reservoir in order to interdict the prevalence of malaria quickly.

(57) 摘要

本发明提供一种治疗多重抗药性恶性疟、间日疟、三日疟等人类疟疾的新药复方青蒿素片及其相关儿童剂型（如颗粒剂、栓剂、混悬糖浆、干粉）。该复方由青蒿素、哌喹、伯氨喹组方制成。通过在东南亚疟疾流行国的临床试验证明，该药不仅具有当前国内外最优秀的青蒿素类复方抗疟药高效的、速效的疗效，而且具有疗程更短、副作用更小、原料成本更低、服用更方便的特点，其快速杀灭配子体，迅速切断传染源以阻断疟疾传播等，更是创新的特点。

WO 2005/030197 A1

Combination comprising artemisinin

Technical field

The present invention relates to medicaments for the treatment of malaria, in particular to a combination comprising artemisinin having high and rapid therapeutic effect.

Background art

Among the prior art anti-malaria drugs, some employ artemisinin derivatives (such as dihydroartemisinin, artesunate, artemether, arteether) in conjunction with piperaquine having a long half-life, which result in long course of treatment, and resistant plasmodia; some employ phosphates of piperaquine and primaquine, which have suboptimal therapeutic effect due to GI tract side effects of said phosphates. In addition, the prior art anti-malaria drugs suffer from the disadvantages of long processing period, high production cost, short shelf life, large dosage and the like.

Disclosure of the invention

The object of the present invention is to overcome the shortcomings in the prior art by providing a combination comprising artemisinin, which requires shorter course of treatment, with less side effect, lower production cost, more convenience for administration, as well as high and rapid therapeutic effect.

The object of the present invention is achieved by a combination comprising artemisinin, which can be formulated into tablets and granules, suppository, suspension syrup or dry powder for pediatric use. The combination comprises artemisinin, piperaquine and primaquine in following ratio ranges:

artemisinin, 1 part

piperaquine, 3-9 parts

primaquine, 0-0.2 part,

the optimum ratio being 1:6:0.6.

The primaquine can also be formulated into a separate tablet to be taken along with a tablet of mixed artemisinin and piperaquine.

It has been shown through clinical trials of more than 600 cases of multiple-resistant subtertian malaria, tertian malaria and quartan malaria that the present drug is characterized by rapid and high therapeutic effect, low toxicity, short course of treatment, and ability of rapidly eliminating infection source to block spreading of malaria, which is obviously superior to domestic and foreign drugs of the same class in terms of therapeutic effect and function.

Embodiment of the Invention

The formulation is as follows:

Artemisinin	120 g
Piperaquine	1200 g
Primaquine	6 g
Adjuvant (hydroxypropyl cellulose and etc.)	q.s.
to produce	1,000 Tablets

The preparation process

Qualified materials are respectively crushed and pass through a screen of 100 meshes. The materials and adjuvant are accurately weighed according to the formulation, and the individual ingredients are homogenously mixed and compressed into tablets or prepared into various dosage forms for pediatric use, which are then packed to give the finished product.

The present combination comprising artemisinin is useful in the treatment of various malaries (human malaria such as subtertian malaria, tertian malaria and quartan malaria), in particular multiple-resistant subtertian malaria. The total dosage for an adult is 2 tablets, with 1 tablet per day.

Primaquine is contained in the present combination in an amount of only 6 mg per tablet, which is the daily dosage and taken for only two days. This dosage is reduced by 82% as compared with a conventional dosage of 67.5 mg in three days. Its use in conjunction with artemisinin, as proved by experiment, can lead to the gametophyte of plasmodium falciparum losing its infectivity completely by 24 h after the first dose, thereby blocking its propagation without any side effect. It is one particular feature possessed by the present combination using an ultra-low dose of primaquine.

Due to its advantages including lower material cost, smaller size, shorter course of treatment, and more convenience for administration (2 tablets in two days for an adult) as well as ability of substantially killing gametophyte to block spreading of malaria, as compared with any artemisinin combinations, the present combination can favorably enter national state hospitals in developing countries at a relatively low price, and is in the interest of global application and dissemination of anti-malaria measures.

9 8

Claims:

1. A combination comprising artemisinin, which can be formulated into tablets or granules, suppository, suspension syrup or dry powder for pediatric use, said combination comprising artemisinin, piperaquine and primaquine in following ratio ranges:

artemisinin 1 part

piperaquine 3-9 parts

primaquine 0-0.2 part,

the optimum ratio being 1:6:0.6.

2. The combination comprising artemisinin according to claim 1, wherein the primaquine can be formulated into a separate tablet to be taken along with a tablet of mixed artemisinin + piperaquine.

Abstract

The present invention provides a novel combination comprising artemisinin in the form of tablets and related dosage forms for pediatric use, such as granules, suppository, suspension syrup and dry powder, for the treatment of human malarias including multiple-resistent subtertian malaria, tertian malaria and quartan malaria. Said combination is comprised of artemisinin, piperaquine and primaquine. Clinical tests in Southeast Asia countries where malaria is epidemic demonstrate that, apart from having high and rapid therapeutic effect possessed by the most excellent domestic and foreign artemisinin-type anti-malarial drugs, the present combination is also featured with shorter course of treatment, less side effect, lower material cost, and more convenience for administration, and its ability of rapidly killing gamatophyte and cutting off infection source thereby blocking spreading of malaria is a further improvement.

4
10

1) A copy of amendment has markings to show the change
(specification 3 pages; claims 1 page ; abstract 1 page)
2) Clean copy
(specification 3 pages; claims 1 pages ; abstract 1 page)

12
11

Combination comprising artemisinin

Technical field

The present invention relates to medicaments for the treatment of malaria, in particular to a combination comprising artemisinin having high and rapid therapeutic effect.

Background art

Among the prior art anti-malaria drugs, some employ artemisinin derivatives (such as dihydroartemisinin, arteaunate, artomether, arteether) in conjunction with piperaquine having a long half-life. GI tract side effects such as nausea and vomiting due to substantial amount of phosphates adversely affect the therapeutic effects, with incidence of up to 10% when the total amount for one course is divided into 3 doses, and reduced to 3-5% when divided into 4 doses. In addition, the prior art anti-malaria drugs suffer from the disadvantages of long processing period, high production cost, short shelf life, large dosage and the like.

[illegible] ., which result in long course of treatment, and resistant plasmodia; some employ phosphates of piperaquine and primaquine, which have suboptimal therapeutic effect due to GI tract side effects of said phosphates.

Disclosure of the invention

The object of the present invention is to overcome the shortcomings in the prior art by providing a combination comprising artemisinin, which requires shorter course of treatment, with less side effect, lower production cost, more convenience for administration, as well as high and rapid therapeutic effect.

The object of the present invention is achieved by a combination comprising artemisinin, which can be formulated into tablets and granules, suppository, suspension syrup or dry powder for pediatric use. The combination comprises artemisinin, piperaquine and primaquine in following ratio ranges:

artemisinin, 1 part

piperaquine, 5 parts

primaquine, 0-0.05 part,

[illegible]: 3-5

[illegible]: 0.2

the optimum ratio being 1:6:0.04. 删除的内容: 1:6:0.1

The primaquine can also be formulated into a separate tablet to be taken along with a tablet of mixed artemisinin and piperaquine.

It has been shown through clinical trials of more than 600 cases of multiple-resistant subtertian malaria, tertian malaria and quartan malaria that the present drug is characterized by rapid and high therapeutic effect, low toxicity, short course of treatment, and ability of rapidly eliminating infection source to block spreading of malaria, which is obviously superior to domestic and foreign drugs of the same class in terms of therapeutic effect and function.

Embodiment of the invention

The formulation is as follows:

Artemisinin	100 g
Piperaquine	750 g
Primaquine	6 g
Adjuvant (hydroxypropyl cellulose and etc.)	q.s.
to produce	1,000 Tablets

删除的内容: 120

删除的内容: 1200

The preparation process

Qualified materials are respectively crushed and pass through a screen of 100 meshes. The materials and adjuvant are accurately weighed according to the formulation, and the individual ingredients are homogenously mixed and compressed into tablets or prepared into various dosage forms for pediatric use, which are then packed to give the finished product.

The present combination comprising artemisinin is useful in the treatment of various malarias (human malaria such as subtertian malaria, tertian malaria and quartan malaria), in particular multiple-resistant subtertian malaria. The

13 xt

total dosage for an adult is 2 tablets, with 1 tablet per day.

Primaquine is contained in the present combination in an amount of only 6 mg per tablet, which is the daily dosage and taken for only two days. This dosage is reduced by 82% as compared with a conventional dosage of 67.5 mg in three days. Its use in conjunction with artemisinin, as proved by experiment, can lead to the gametophyte of plasmodium falciparum losing its infectivity completely by 24 h after the first dose, thereby blocking its propagation without any side effect. It is one particular feature possessed by the present combination using an ultra-low dose of primaquine.

Due to its advantages including lower material cost, smaller size, shorter course of treatment, and more convenience for administration (2 tablets in two days for an adult) as well as ability of substantially killing gametophyte to block spreading of malaria, as compared with any artemisinin combinations, the present combination can favorably enter national state hospitals in developing countries at a relatively low price, and is in the interest of global application and dissemination of anti-malaria measures.

Claims:

1. A combination comprising artemisinin, which can be formulated into tablets or granules, suppository, suspension syrup or dry powder for pediatric use, said combination comprising artemisinin, piperaquine and primaquine in following ratio ranges:

artemisinin 1 part

piperaquine 5 parts

primaquine 0-0.05 part,

the optimum ratio being 1:5:0.04.

2. The combination comprising artemisinin according to claim 1, wherein the primaquine can be formulated into a separate tablet to be taken along with a tablet of mixed artemisinin + piperaquine.

16
15

Abstract

The present invention provides a novel combination comprising artemisinin in the form of tablets and related dosage forms for pediatric use, such as granules, suppository, suspension syrup and dry powder, for the treatment of human malarias including multiple-resistant subtertian malaria, tertian malaria and quartan malaria. Said combination is comprised of artemisinin, piperaquine and primaquine. Clinical tests in Southeast Asia countries where malaria is epidemic demonstrate that, apart from having high and rapid therapeutic effect possessed by the most excellent domestic and foreign artemisinin-type anti-malarial drugs, the present combination is also featured with shorter course of treatment, less side effect, lower material cost, and more convenience for administration, and its ability of rapidly killing gametophyte and cutting off infection source thereby blocking spreading of malaria is a further improvement.

17
16

Combination comprising artemisinin

Technical field

The present invention relates to medicaments for the treatment of malaria, in particular to a combination comprising artemisinin having high and rapid therapeutic effect.

Background art

Among the prior art anti-malaria drugs, some employ artemisinin derivatives (such as dihydroartemisinin, artesunate, artemether, arteether) in conjunction with piperaquine having a long half-life. GI tract side effects such as nausea and vomiting due to substantial amount of phosphates adversely affect the therapeutic effects, with incidence of up to 10% when the total amount for one course is divided into 3 doses, and reduced to 3-5% when divided into 4 doses. In addition, the prior art anti-malaria drugs suffer from the disadvantages of long processing period, high production cost, short shelf life, large dosage and the like.

Disclosure of the invention

The object of the present invention is to overcome the shortcomings in the prior art by providing a combination comprising artemisinin, which requires shorter course of treatment, with less side effect, lower production cost, more convenience for administration, as well as high and rapid therapeutic effect.

The object of the present invention is achieved by a combination comprising artemisinin, which can be formulated into tablets and granules, suppository, suspension syrup or dry powder for pediatric use. The combination comprises artemisinin, piperaquine and primaquine in following ratio ranges:

artemisinin, 1 part
piperaquine, 5 parts
primaquine, 0-0.05 part,

17

the optimum ratio being 1:5:0.04.

The primaquine can also be formulated into a separate tablet to be taken along with a tablet of mixed artemisinin and piperaquine.

It has been shown through clinical trials of more than 600 cases of multiple-resistant subtertian malaria, tertian malaria and quartan malaria that the present drug is characterized by rapid and high therapeutic effect, low toxicity, short course of treatment, and ability of rapidly eliminating infection source to block spreading of malaria, which is obviously superior to domestic and foreign drugs of the same class in terms of therapeutic effect and function.

Embodiment of the Invention

The formulation is as follows:

Artemisinin	160 g
Piperaquine	750 g
Primaquine	6 g
Adjuvant (hydroxypropyl cellulose and etc.)	q.s.
to produce	1,000 Tablets

The preparation process

Qualified materials are respectively crushed and pass through a screen of 100 meshes. The materials and adjuvant are accurately weighed according to the formulation, and the individual ingredients are homogenously mixed and compressed into tablets or prepared into various dosage forms for pediatric use, which are then packed to give the finished product.

The present combination comprising artemisinin is useful in the treatment of various malarias (human malaria such as subtertian malaria, tertian malaria and quartan malaria), in particular multiple-resistant subtertian malaria. The

total dosage for an adult is 2 tablets, with 1 tablet per day.

Primaquine is contained in the present combination in an amount of only 6 mg per tablet, which is the daily dosage and taken for only two days. This dosage is reduced by 82% as compared with a conventional dosage of 67.5 mg in three days. Its use in conjunction with artemisinin, as proved by experiment, can lead to the gametophyte of plasmodium falciparum losing its infectivity completely by 24 h after the first dose, thereby blocking its propagation without any side effect. It is one particular feature possessed by the present combination using an ultra-low dose of primaquine.

Due to its advantages including lower material cost, smaller size, shorter course of treatment, and more convenience for administration (2 tablets in two days for an adult) as well as ability of substantially killing gametophyte to block spreading of malaria, as compared with any artemisinin combinations, the present combination can favorably enter national state hospitals in developing countries at a relatively low price, and is in the interest of global application and dissemination of anti-malaria measures.

20
19

Claims:

1. A combination comprising artemisinin, which can be formulated into tablets or granules, suppository, suspension syrup or dry powder for pediatric use, said combination comprising artemisinin, piperaquine and primaquine in following ratio ranges:

artemisinin 1 part

piperaquine 5 parts

primaquine 0-0.05 part,

the optimum ratio being 1:5:0.04.

2. The combination comprising artemisinin according to claim 1, wherein the primaquine can be formulated into a separate tablet to be taken along with a tablet of mixed artemisinin + piperaquine.

Abstract

The present invention provides a novel combination comprising artemisinin in the form of tablets and related dosage forms for pediatric use, such as granules, suppository, suspension syrup and dry powder, for the treatment of human malarias including multiple-resistant subtertian malaria, tertian malaria and quartan malaria. Said combination is comprised of artemisinin, piperaquine and primaquine. Clinical tests in Southeast Asia countries where malaria is epidemic demonstrate that, apart from having high and rapid therapeutic effect possessed by the most excellent domestic and foreign artemisinin-type anti-malarial drugs, the present combination is also featured with shorter course of treatment, less side effect, lower material cost, and more convenience for administration, and its ability of rapidly killing gametophyte and cutting off infection source thereby blocking spreading of malaria is a further improvement.

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

FIRST NOTICE INFORMING THE APPLICANT OF THE COMMUNICATION OF THE INTERNATIONAL APPLICATION (TO DESIGNATED OFFICES WHICH DO NOT APPLY THE 30 MONTH TIME LIMIT UNDER ARTICLE 22(1))

(PCT Rule 47.1(c))

To:

GUANGZHOU NANFENG PATENT AGENT LIMITED
2/F, Experiment Bldy., NO. 100
Xianlie Road, M.
Guangzhou
Guangdong 510070
SENEGAL

Date of mailing (day/month/year)	
28 April 2005 (28.04.2005)	
Applicant's or agent's file reference	IMPORTANT NOTICE
NF20040003	

International application No.	International filing date (day/month/year)	Priority date (day/month/year)
PCT/CN2004/001064	20 September 2004 (20.09.2004)	26 September 2003 (26.09.2003)

Applicant: LI, Guoqiao et al

1. ATTENTION: For any designated Office(s), for which the time limit under Article 22(1), as in force from 1 April 2002 (30 months from the priority date), does apply, please see Form PCT/IB/338(Second and Supplementary Notice) (to be issued promptly after the expiration of 28 months from the priority date).

2. Notice is hereby given that the following designated Office(s), for which the time limit under Article 22(1), as in force from 1 April 2002, does not apply, has/have requested that the communication of the international application, as provided for in Article 20, be effected under Rule 93*bis*.1. The International Bureau has effected that communication on the date indicated below:
07 April 2005 (07.04.2005)

CH 指定

In accordance with Rule 47.1(c-*bis*)(i), those Offices will accept the present notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).

3. The following designated Offices, for which the time limit under Article 22(1), as in force from 1 April 2002, does not apply, have not requested, as at the time of mailing of the present notice, that the communication of the international application be effected under Rule 93*bis*.1:

LU, SE, TZ, UG, ZM 卢森堡、瑞典、坦桑尼亚、乌干达、赞比亚

In accordance with Rule 47.1(c-*bis*)(ii), those Offices accept the present notice as conclusive evidence that the Contracting State for which that Office acts as a designated Office does not require the furnishing, under Article 22, by the applicant of a copy of the international application.

4. TIME LIMITS for entry into the national phase 进入国家阶段的期限

For the designated Office(s) listed above, and unless a demand for international preliminary examination has been filed before the expiration of 19 months from the priority date (see Article 39(1)), the applicable time limit for entering the national phase will, subject to what is said in the following paragraph, be 20 MONTHS from the priority date.

In practice, time limits other than the 20-month time limit will continue to apply, for various periods of time, in respect of certain of the designated Offices listed above. For regular updates on the applicable time limits (20 or 21 months, or other time limit), Office by Office, refer to the *PCT Gazette*, the *PCT Newsletter* and the *PCT Applicant's Guide*, Volume II, National Chapters, all available from WIPO's Internet site, at http://www.wipo.int/pct/en/index.html.

It is the applicant's sole responsibility to monitor all these time limits.

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Nora Lindner
Facsimile No. +41 22 740 14 35	Facsimile No. +41 22 338 89 65

Form PCT/IB/301(First Notice) (January 2004)

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION CONCERNING SUBMISSION OR TRANSMITTAL OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

To:

GUANGZHOU NANFENG PATENT AGENT LIMITED
2/F, Experiment Bldy., NO. 100
Xianlie Road, M.
Guangzhou
Guangdong 510070
Senegal

Date of mailing (day/month/year) 06 December 2004 (06.12.2004)	
Applicant's or agent's file reference NF20040003	IMPORTANT NOTIFICATION
International application No. PCT/CN2004/001064	International filing date (day/month/year) 20 September 2004 (20.09.2004)
International publication date (day/month/year) Not yet published	Priority date (day/month/year) 26 September 2003 (26.09.2003)
Applicant LI, Guoqiao et al	

1. By means of this Form, which replaces any previously issued notification concerning submission or transmittal of priority documents, the applicant is hereby notified of the date of receipt by the International Bureau of the priority document(s) relating to all earlier application(s) whose priority is claimed. Unless otherwise indicated by the letters "NR", in the right-hand column or by an asterisk appearing next to a date of receipt, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).

2. (If applicable) The letters "NR" appearing in the right-hand column denote a priority document which, on the date of mailing of this Form, had not yet been received by the International Bureau under Rule 17.1(a) or (b). Where, under Rule 17.1(a), the priority document must be submitted by the applicant to the receiving Office or the International Bureau, but the applicant fails to submit the priority document within the applicable time limit under that Rule, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

3. (If applicable) An asterisk(*) appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b) (the priority document was received after the time limit prescribed in Rule 17.1(a) or the request to prepare and transmit the priority document was submitted to the receiving Office after the applicable time limit under Rule 17.1(b)). Even though the priority document was not furnished in compliance with Rule 17.1(a) or (b), the International Bureau will nevertheless transmit a copy of the document to the designated Offices, for their consideration. In case such a copy is not accepted by the designated Office as priority document, Rule 17.1(a) provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

Priority date	Priority application No.	Country or regional Office or PCT receiving Office	Date of receipt of priority document
26 Sept 2003 (26.09.2003)	03146951.5	CN	01 Dece 2004 (01.12.2004)

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Rodrigo GARCIA CONDE
Facsimile No. (41-22) 338.89.05	Telephone No. (41-22) 338 9828

Form PCT/IB/304 (January 2004) 006528979

20

SUPERINTENDENCIA Y COMERCIO
Radicacion : 06029537 [illegible] Folios: 23
Fecha (DD): 2006-03-24 16:41:57
Tramite : 011 PCT-PATENT 370 FASE NACI 411 PRESENTAC
Dependencia: 2020 DIVISION DE NUEVAS CREACIONES

Industria y Comercio
SUPERINTENDENCIA

23

Delegatura de Propiedad Industrial
División de Nuevas Creaciones

REQUISITOS NECESARIOS PARA PRESENTACIÓN Y AGILIZACIÓN DEL TRAMITE

	USUARIO	RADICADOR
PATENTE DE INVENCIÓN (✓) MODELO DE UTILIDAD ( )	( )	( )
-Indicación de que se solicita la concesión de una patente.	( )	(✓)
-Datos de identificación del solicitante o de la persona que se presenta la solicitud.	( )	(✓)
-Descripción de la invención.	( )	(✓)
-Dibujos de ser estos pertinentes.	( )	(X)
-Comprobante de Pago de las tasas establecidas.	( )	(✓)
COMPLETA ( ) INCOMPLETA ( )	( )	( )
DISEÑO INDUSTRIAL ( )		
-Indicación de que se solicita el registro de Diseño Industrial.	( )	( )
-Datos de identificación del solicitante o de la persona que se presenta la solicitud.	( )	( )
-Representación gráfica y fotográfica del Diseño Industrial o muestra del Material que incorpora el diseño.	( )	( )
-Comprobante de Pago de las tasas establecidas.	( )	( )
COMPLETA ( ) INCOMPLETA ( )	( )	( )
ESQUEMA DE TRAZADO ( )		
-Indicación de que se solicita el registro de Diseño Industrial.	( )	( )
-Datos de identificación del solicitante o de la persona que se presenta la solicitud.	( )	( )
-Representación gráfica del Esquema Trazado.	( )	( )
-Comprobante de Pago de las tasas establecidas.	( )	( )
COMPLETA ( ) INCOMPLETA ( )	( )	( )

Firma Responsable: [signature]

Fecha: marzo 24 de 2006

PETITORIO

Industria y Comercio
SUPERINTENDENCIA

SUPERINDUSTRIA Y COMERCIO
Radicación : [illegible] [illegible] Folios: [illegible]
Fecha (RAD): [illegible] [illegible]
Tramite : [illegible] PCT-PATENT [illegible]
Dependencia: [illegible] DIVISION DE NUEVAS CREACIONES

FORMULARIO ÚNICO DE SOLICITUD DE PATENTE
PCT
ENTRADA EN FASE NACIONAL : 26-04-2006

① SOLICITUD DE :

[X] Patente de Invención. [ ] Patente de Modelo de Utilidad.

[X] Capítulo I. [ ] Capítulo II.

② SOLICITANTE (71)	Nombre: GUOQIAO LI y JIANPING SONG Dirección: Room 601, Building 66, 12 Airport RD, Guangzhou, Guangdong 510405, China Nacionalidad o Domicilio: CHINA Lugar de Constitución: Teléfono: Fax: E-mail:	IDENTIFICACIÓN C.C. [ ] NIT [ ] C.E. [ ] Otro [ ] Cual ____ Número ____
③ REPRESENTANTE O APODERADO	Nombre. LAURA MICHELSEN NIÑO Dirección: CALLE 93B No. 12 - 48. Of. 204 Teléfono: 601 9660 Fax: 611 4209 E-mail: lum@lumnet.com	IDENTIFICACIÓN C.C. [X] NIT [ ] C.E. [ ] Otro [ ] Cual ____ Número 39.783.287 TP 67.89
④ INVENTOR (ES) (72)	Nombre: GUOQIAO LI y JIANPING SONG Dirección: Room 601, Building 66, 12 Airport RD, Guangzhou, Guangdong 510405, China Nacionalidad o Domicilio CHINA	

⑤ PCT (86)

Solicitud Internacional No. PCT/CN2004/001084 Fecha 20-09-2004

Publicación Internacional No. WO/2005/030197 Fecha 07-04-2005

⑥ Título (54) COMPUESTO ARTEMISININA

⑦ Clasificación Internacional (51) A61K 31/336, A61K 31/4706, A61K 31/496, A61P 33/06

⑧ Prioridad SI [X] NO [ ]

(33) País de Origen	(32) Fecha	(31) Número de Solicitud
CHINA	26/09/2003	03146951.5